The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2017 | Exploring and consolidating the CLL world
Ulrich Jäger, MD from the Medical University of Vienna, Vienna, Austria tells us about his personal highlights regarding chronic lymphocytic leukemia (CLL) from the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. He is particularly excited about new drug combinations, specifically venetoclax and obinutuzumab which have shown very positive results. However he believes that the medical community are still exploring the CLL world.
